Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function

British Journal of Clinical Pharmacology, Supplement

Volumn 58, Issue 1, 2004, Pages 18-24

  Nagy, Christa F ^a   Kumar, Dinesh ^a   Cullen, Edward I ^a,f   Bolton, W Kline ^b   Marbury, Thomas C ^c   Gutierrez, Maria J ^d   Hutman, H Wayne ^e,g   Pratt, Raymond D ^a,h  

^a EISAI INC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

^d Comprehensive Phase One ^*  (United States)

^e South Florida Bioavailability Clinic   (United States)

^f Johnson/Johnson Consum Prod Co ^*

^g JOHNSON AND JOHNSON   (United States)

^h SHIRE   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Pharmacokinetics; Renal impairment

Indexed keywords

ACETYLCHOLINESTERASE; CREATINE; DONEPEZIL; CHOLINESTERASE;

ADULT; AGED; AREA UNDER THE CURVE; BODY SURFACE; BODY WEIGHT; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LEG FRACTURE; MALE; NAUSEA; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RIGIDITY; SIDE EFFECT; STEADY STATE; VIRUS INFECTION; ARTICLE; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG TOLERANCE; KIDNEY DISEASE; MULTIPLE DRUG DOSE; SINGLE DRUG DOSE;

EID: 8844254692     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.01803.x     Document Type: Review

References (16)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 1403.
2. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl) methyl]piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821-9.
3. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
4. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
5. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
6. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
7. 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46(Suppl. 1): 19-24.
8. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 1-6.
9. Abreu PF, Ramos LR, Sesso R. Abnormalities of renal function in the elderly. Geriatr Nephrol Ural 1999; 9: 141-5.
10. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998; 46(Suppl. 1): 56-60.
11. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 7-12.
12. Height and Weight Standards. New York: Metropolitan Life Insurance Company, 1983.
13. Voehringer H-F, Rietbrock N. Digitalis therapy in renal failure with special regard to digitoxin. Intern J Clin Pharmacol Toxicol 1981; 19: 175-84.
14. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, Tanaka T. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086-91.
15. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46(Suppl. 1): 13-18.
16. ARICEPT® (donepezil hydrochloride tablets). US package insert, December 2000. Teaneck, NJ: Eisai Inc.